New oversight put in place for physicians giving anemia drugs to patients with cancer.
Mitka
Mike
M
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000970:Antineoplastic Agents / Q000009:adverse effects; D000068256:Darbepoetin alfa; D004282:Documentation; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006291:Health Policy; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins; D012308:Risk Management; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa